Log in to save to my catalogue

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyng...

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyng...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1834995309

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

About this item

Full title

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2016-10, Vol.388 (10054), p.1883-1892

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Outcomes are poor for patients with recurrent or metastatic nasopharyngeal carcinoma and no well established first-line chemotherapy is available for the disease. We compared the efficacy and safety of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma....

Alternative Titles

Full title

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1834995309

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1834995309

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(16)31388-5

How to access this item